LP
APLS

LMR Partners’s Apellis Pharmaceuticals APLS Stock Holding History

LMR Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,300
Closed -$810K – 990
2023
Q3 		$810K Buy
+21,300
New +$936K 0.01% 511

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

LMR Partners's APLS Position: Q1 2026 in Review

LMR Partners opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 403,622 shares worth $16.2M. The stake represents 0.04% of the portfolio and ranks #264 among its holdings. This is a return to the name: LMR Partners previously reported a position in APLS as recently as Q2 2024.

LMR Partners first reported a position in APLS in Q3 2021 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • LMR Partners held 403,622 shares of Apellis Pharmaceuticals worth $16.2M as of Q1 2026.
  • Apellis Pharmaceuticals was a new LMR Partners position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.04% of LMR Partners's portfolio in Q1 2026, its #264 holding.
  • LMR Partners first reported a position in Apellis Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.